Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
复制标题
DOI：
10.1126/sciimmunol.abq4450
复制
发表时间：
2022-09-23
影响因子：
24.8
通讯作者：
中科院分区：
文献类型：
--
作者：
SARS-CoV-2变异株的出现和快速传播可能会显著影响疫苗的有效性。Omicron变异体BA.2与BA.1在基因序列上有很大不同，目前在几个国家正在取代BA.1，但其抗原特性尚未得到评估。在这里，我们使用抗原制图来量化和可视化早期SARS-CoV-2变体（614 G，Alpha，Beta，Gamma，Zeta，Delta和Mu）之间的抗原差异，使用初次感染后获得的仓鼠抗血清。我们首先验证了用于中和测定的细胞系的选择基本上不影响图谱的拓扑结构。在广泛使用的VeroE 6细胞系和人气道细胞系Calu-3上使用假型SARS-CoV-2产生的抗原图谱产生了类似的图谱。用真正的SARS-CoV-2在Calu-3细胞上绘制的图谱也与用假型病毒生成的图谱非常相似。抗原图谱揭示了SARS-CoV-2变体的中心簇，这些变体根据相互的刺突突变进行分组。尽管这些早期变体在抗原性上是相似的，在抗原性空间中彼此相对接近地聚集，但Omicron BA.1和BA.2已经进化为两个不同的抗原性离群值。我们的数据表明，BA.1和BA.2都逃避疫苗诱导的抗体反应，由于不同的抗原特性。因此，抗原制图可用于评估未来出现的SARS-CoV-2变异的抗原特性，并决定新的基于刺突（加强）疫苗的组成。SARS-CoV-2的抗原进化可以通过抗原制图来监测，为未来的冠状病毒疫苗株选择提供信息。
The emergence and rapid spread of SARS-CoV-2 variants may impact vaccine efficacy significantly. The Omicron variant termed BA.2, which differs substantially from BA.1 based on genetic sequence, is currently replacing BA.1 in several countries, but its antigenic characteristics have not yet been assessed. Here, we used antigenic cartography to quantify and visualize antigenic differences between early SARS-CoV-2 variants (614G, Alpha, Beta, Gamma, Zeta, Delta and Mu) using hamster antisera obtained after primary infection. We first verified that the choice of the cell line for the neutralization assay did not affect the topology of the map substantially. Antigenic maps generated using pseudotyped SARS-CoV-2 on the widely used VeroE6 cell line and the human airway cell line Calu-3 generated similar maps. Maps made using authentic SARS-CoV-2 on Calu-3 cells also closely resembled those generated with pseudotyped viruses. The antigenic maps revealed a central cluster of SARS-CoV-2 variants, which grouped based on mutual spike mutations. Whereas these early variants are antigenically similar, clustering relatively close to each other in antigenic space, Omicron BA.1 and BA.2 have evolved as two distinct antigenic outliers. Our data show that BA.1 and BA.2 both escape vaccine-induced antibody responses as a result of different antigenic characteristics. Thus, antigenic cartography could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines. Antigenic evolution by SARS-CoV-2 can be monitored by antigenic cartography, informing future coronavirus vaccine strain selections.
登录
查看更多内容
影响因子：
64.8
作者：
Muñoz-Fontela C;Dowling WE;Funnell SGP;Gsell PS;Riveros-Balta AX;Albrecht RA;Andersen H;Baric RS;Carroll MW;Cavaleri M;Qin C;Crozier I;Dallmeier K;de Waal L;de Wit E;Delang L;Dohm E;Duprex WP;Falzarano D;Finch CL;Frieman MB;Graham BS;Gralinski LE;Guilfoyle K;Haagmans BL;Hamilton GA;Hartman AL;Herfst S;Kaptein SJF;Klimstra WB;Knezevic I;Krause PR;Kuhn JH;Le Grand R;Lewis MG;Liu WC;Maisonnasse P;McElroy AK;Munster V;Oreshkova N;Rasmussen AL;Rocha-Pereira J;Rockx B;Rodríguez E;Rogers TF;Salguero FJ;Schotsaert M;Stittelaar KJ;Thibaut HJ;Tseng CT;Vergara-Alert J;Beer M;Brasel T;Chan JFW;García-Sastre A;Neyts J;Perlman S;Reed DS;Richt JA;Roy CJ;Segalés J;Vasan SS;Henao-Restrepo AM;Barouch DH
通讯作者：
Barouch DH
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
4
作者：
Potter, CW
通讯作者：
Potter, CW
影响因子：
56.9
作者：
Lamers, Mart M.;Beumer, Joep;Clevers, Hans
通讯作者：
Clevers, Hans
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK